HRS-3/A9

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHRS-3/A9

Drug Alias NameHRS-3/A9Anti-CD16/CD30 BiMAb

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 modulatorsLow affinity immunoglobulin gamma Fc region receptor III-A modulators

TargetsLow affinity immunoglobulin gamma Fc region receptor III-ATumor necrosis factor receptor superfamily member 8

Therapy Area/IndicationsHodgkin Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiotest Pharma Gmbh University Of Saarland

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of Saarland Biotest Ag

Active IndicationsN/A

Inactive IndicationsHodgkin Disease

Other Information

ATC CodeN/A